Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317379 | 1.00 | MTNR1A (0.34) | MTNR1AMTNR1BHTR3AAVPR1BMEN1 | |
| SCHEMBL2317375 | 1.00 | MTNR1A (0.34) | MTNR1AMTNR1BHTR3AAVPR1BMEN1 | |
| SCHEMBL12390181 | 0.92 | KLKB1 (0.36) | MTNR1AMTNR1BHTR3AMEN1KMT2A | |
| SCHEMBL2319496 | 0.86 | MTNR1A (0.35) | MTNR1AMTNR1B | |
| SCHEMBL2315383 | 0.85 | PDE1A (0.36) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL2319162 | 0.84 | MTNR1A (0.34) | MTNR1AMTNR1B | |
| SCHEMBL2315050 | 0.83 | MTNR1A (0.32) | MTNR1AMTNR1BMEN1KMT2A | |
| SCHEMBL15875796 | 0.82 | MTNR1A (0.36) | MTNR1AMTNR1B | |
| SCHEMBL2319844 | 0.81 | MTNR1A (0.39) | MTNR1AMTNR1B | |
| SCHEMBL2321987 | 0.80 | MTNR1A (0.37) | MTNR1AMTNR1BDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8785639-B2 | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof | ABBVIE INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20110190489-A1 | Novel Tricyclic Compounds | ABBOTT LABORATORIES (US) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349970-A1 | NOVEL TRICYCLIC COMPOUNDS | CCNI, IL2, IL4I1 | MTNR1A 1322/4885MTNR1B 826/4885HTR3A 1577/4885 |
| US-20110190489-A1 | Novel Tricyclic Compounds | CCNI, IL2, IL4I1 | MTNR1A 1322/4885MTNR1B 826/4885HTR3A 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.